Uster

Researchers are evaluating the effects of lysergic acid diethylamide LSD on psychosocial distress in patients with advanced or end-stage fatal diseases who have a life expectancy between 12 weeks and 2 years. This phase II, randomized, double-blind, active placebo-controlled study aims to assess changes in depressive symptoms, anxiety, pain, quality of life, spiritual well-being, demoralization, and caregiver burden among 60 participants. Participants will be randomly assigned in a 21 ratio to one of two groups. The treatment group will receive two moderate to high oral doses of LSD 100 g followed by either 100 g or 200 g, while the control group will receive two low doses of LSD 25 g for both sessions as an active placebo. The study involves two dosing sessions with assessments at multiple time points. During the study, participants will complete various questionnaires and evaluations measuring anxiety state anxiety inventory, pain levels, opioid use, spiritual well-being, demoralization, quality of life, and other psychological and behavioral factors. Assessments occur before and after each intervention, including follow-ups up to 9 weeks after the second dose. Researchers will also monitor adverse events, vital signs during dosing sessions, and collect qualitative data through interviews. Total participation duration extends up to about 9 weeks after the last intervention.

Gastroentero-pancreatic neuroendocrine tumours GEP-NETs are rare cancers arising from the neuroendocrine cells in the gastrointestinal tract and pancreas. These tumours share common clinical features but their cell biology and mechanisms are not well understood, limiting targeted treatments. The SwissNET registry is designed to collect detailed information to better understand GEP-NETs and improve management strategies in Switzerland. This study collects data prospectively from patients diagnosed with neuroendocrine tumours confirmed by tissue analysis, regardless of the tumours original location. Data entry is anonymized and gathered from hospitals and general practitioners across Switzerland. A study nurse visits contributing centers to review patient files, and a review board addresses conflicting information. The registry monitors treatment approaches including surgery, medical therapy, and peptide-receptor radionuclide therapy. Participants provide informed consent for their data to be included. Researchers regularly evaluate patient outcomes such as tumour-related mortality and hospitalisation rates every five years. The registry also tracks the incidence of GEP-NETs in Switzerland and the effects of different treatments over time. This ongoing data collection aims to improve understanding and guide future care for patients with neuroendocrine tumours.

Researchers are studying the medical care and treatment of patients with moderate-to-severe atopic dermatitis AD, a common chronic inflammatory skin condition that significantly affects quality of life and has economic impact. This national, prospective, multicenter registry in Switzerland aims to fill the gap in detailed data on how AD is managed and to assess the safety and effectiveness of approved therapies in real-world settings. The study includes children aged 12 years and older, adolescents, and adults with moderate-to-severe AD. No experimental treatments are given as part of the study. Instead, patients are followed for at least 24 months with periodic visits to document their clinical information, treatments, patient-reported outcomes, and reasons for treatment choices. Participants will undergo standardized assessments over the observation period to record demographic data, treatment history, comorbidities, and changes in disease severity using tools like SCORAD, EASI, DLQI, POEM, and RECAP. The study primarily evaluates the types of systemic therapies used, while also monitoring quality of life and disease progression. There is no maximum follow-up duration, allowing long-term data collection.